SCH 486757

Drug Profile

SCH 486757

Alternative Names: SCH-486757

Latest Information Update: 12 Jun 2013

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Merck & Co
  • Class Antitussives
  • Mechanism of Action Nociceptin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Cough

Most Recent Events

  • 01 Jan 2013 Discontinued - Phase-II for Cough in United Kingdom (PO)
  • 04 Nov 2009 Schering-Plough has been acquired and merged into Merck & Co
  • 30 Nov 2007 Schering-Plough initiates enrolment in a phase II trial for Cough in the UK (NCT00506987)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top